| Name | Title | Contact Details |
|---|
Midwest Health Plan is a Dearborn, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Why American Addiction Centers? We take a big picture approach to addiction recovery treatment – addressing the individual`s whole lifestyle in relation to substance use, alcohol and binge eating addiction and partnering with the family throughout the treatment process whenever possible. With our research-based programs, our inpatient treatment centers don`t just focus on the problem; we strengthen the individual and focus on the future. Whether it`s the initial clinical assessments, medically supervised detox, residential rehabilitation or aftercare, our team is present for and committed to each step of the recovery process for every individual. American Addiction Centers is an equal opportunity and drug free employer. All decisions regarding recruiting and hiring will be made without unlawful discrimination on the basis of race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, or age.
Utah Medical Products, Inc. is a Midvale, UT-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Success Healthcare, LLC. is an organization that manages and owns community-based acute care hospitals supported by a management team dedicated to operations and financial excellence. Our goal is to deliver consistent quality cost-efficient patient care, and programs that best serve as well as respect each individual hospital`s distinctive mission and values, its physicians, employees, and community-at-large. To do so, we provide expertise in operations, clinical, and financial resources to each of our hospitals. To deliver quality and compassionate healthcare to our patients through our employees and the physicians who practice in the communities we serve.
Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates. These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending. Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™. The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee. Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema. Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.